AstraZeneca PLC (AZN.L) and Daiichi Sankyo Company Limited (DSKYF.PK) Wednesday reported positive results from the DESTINY-Breast11 Phase III study of Enhertu. The study met its primary goal of pathologic complete response (pCR), which is the absence of invasive disease in the breast and lymph nodes.
Data from the study showed that Enhertu followed by chemotherapy drugs paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pCR rate versus standard of care when used before surgery in patients with high-risk, locally advanced HER2-positive early-stage breast cancer.
The companies said that this is the first Phase 3 study to demonstrate the benefit of Enhertu in early breast cancer.
Enhertu is already approved for the treatment of various cancers including different types breast cancer, gastric cancer, lung cancer, and solid tumors. The drug is also being evaluated in several ongoing breast cancer trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.